Cargando…
S103: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE PKR ACTIVATOR ETAVOPIVAT (FT-4202) IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812077/ http://dx.doi.org/10.1097/01.HS9.0000821380.12178.0d |
| _version_ | 1784644570847379456 |
|---|---|
| author | Lal, A. Brown, C. Coates, T. Kalfa, T. Kwiatkowski, J.L. Brevard, J. Trenor, C. Wood, K. Sheth, S. |
| author_facet | Lal, A. Brown, C. Coates, T. Kalfa, T. Kwiatkowski, J.L. Brevard, J. Trenor, C. Wood, K. Sheth, S. |
| author_sort | Lal, A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8812077 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-88120772022-02-18 S103: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE PKR ACTIVATOR ETAVOPIVAT (FT-4202) IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE Lal, A. Brown, C. Coates, T. Kalfa, T. Kwiatkowski, J.L. Brevard, J. Trenor, C. Wood, K. Sheth, S. Hemasphere Oral Presentations Lippincott Williams & Wilkins 2022-01-31 /pmc/articles/PMC8812077/ http://dx.doi.org/10.1097/01.HS9.0000821380.12178.0d Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Oral Presentations Lal, A. Brown, C. Coates, T. Kalfa, T. Kwiatkowski, J.L. Brevard, J. Trenor, C. Wood, K. Sheth, S. S103: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE PKR ACTIVATOR ETAVOPIVAT (FT-4202) IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE |
| title | S103: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE PKR ACTIVATOR ETAVOPIVAT (FT-4202) IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE |
| title_full | S103: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE PKR ACTIVATOR ETAVOPIVAT (FT-4202) IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE |
| title_fullStr | S103: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE PKR ACTIVATOR ETAVOPIVAT (FT-4202) IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE |
| title_full_unstemmed | S103: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE PKR ACTIVATOR ETAVOPIVAT (FT-4202) IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE |
| title_short | S103: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE PKR ACTIVATOR ETAVOPIVAT (FT-4202) IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE |
| title_sort | s103: trial in progress: a phase 2, open-label study evaluating the safety and efficacy of the pkr activator etavopivat (ft-4202) in patients with thalassemia or sickle cell disease |
| topic | Oral Presentations |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812077/ http://dx.doi.org/10.1097/01.HS9.0000821380.12178.0d |
| work_keys_str_mv | AT lala s103trialinprogressaphase2openlabelstudyevaluatingthesafetyandefficacyofthepkractivatoretavopivatft4202inpatientswiththalassemiaorsicklecelldisease AT brownc s103trialinprogressaphase2openlabelstudyevaluatingthesafetyandefficacyofthepkractivatoretavopivatft4202inpatientswiththalassemiaorsicklecelldisease AT coatest s103trialinprogressaphase2openlabelstudyevaluatingthesafetyandefficacyofthepkractivatoretavopivatft4202inpatientswiththalassemiaorsicklecelldisease AT kalfat s103trialinprogressaphase2openlabelstudyevaluatingthesafetyandefficacyofthepkractivatoretavopivatft4202inpatientswiththalassemiaorsicklecelldisease AT kwiatkowskijl s103trialinprogressaphase2openlabelstudyevaluatingthesafetyandefficacyofthepkractivatoretavopivatft4202inpatientswiththalassemiaorsicklecelldisease AT brevardj s103trialinprogressaphase2openlabelstudyevaluatingthesafetyandefficacyofthepkractivatoretavopivatft4202inpatientswiththalassemiaorsicklecelldisease AT trenorc s103trialinprogressaphase2openlabelstudyevaluatingthesafetyandefficacyofthepkractivatoretavopivatft4202inpatientswiththalassemiaorsicklecelldisease AT woodk s103trialinprogressaphase2openlabelstudyevaluatingthesafetyandefficacyofthepkractivatoretavopivatft4202inpatientswiththalassemiaorsicklecelldisease AT sheths s103trialinprogressaphase2openlabelstudyevaluatingthesafetyandefficacyofthepkractivatoretavopivatft4202inpatientswiththalassemiaorsicklecelldisease |